Back to press

Global Vision Biotechnologies Confirm Research Program In To Multiple Use CBD Vape Formulas Nearing Completion

  • Date: 07/07/19
  • Author: Daniel Mathers
  • Team: Global Vision Biotechnologies - Press Team

Global Vision Biotechnologies is a leading marijuana research and development biotech company who recently announced it was developing CBD formulas for use in vaping delivery techniques.

Vaping has now become one of the fastest growing markets within the sector and the company are positioning themselves to take full advantage of the explosive growth potential that this form of precise dosage delivery offers the user.

The company’s research program has focused solely on the use of CBD used for medicinal purposes but announced that upon completion of this program they will explore vaping formulas that can be used for the use of recreational marijuana.

The vaping of marijuana, both for medicinal and recreational use, is taking the world by storm and, although vaping has grown by leaps and bounds over the last few years, 2019 is when forecasters expect this form of delivery technique to become firmly established and see usage increase exponentially.

This chart from Wells Fargo shows the market’s growth has grown by more than $12 billion over the past 5 years and is forecast to grow by at least another $5 billion over just the next 2 years.

This is the kind of growth that leads to huge gains for investors who move in early and is why Global Vision Biotechnologies are continuing to advance their research programs in to the vape technology sector as it moves from early-adopters phase to the mainstream phase and is why it’s going to grow by the billions in this year and beyond.

“Our current program in to CBD vape delivery systems has clearly determined that exact dosage administration can be delivered using a single-use capsule. Furthermore, by administering the dosage via a vapor ensures immediate absorption in to the blood stream and with it immediate effect from the dosage, a win-win for patients reliant upon medicinal marijuana medication,” said Michael Lorthe, Ph.D., Head of Product Development with Global Vision Biotechnologies.

“As a company we will be further expanding our vape research programs to develop further CBD formulas and dosages to treat more patient symptoms. Also, we will not discount utilizing this research to assist with the development of recreational use marijuana vape formulas, which in time as legislation for recreational use grows, will become another enormous market in itself,” Lorthe added.